Streetbeat News

XCUR

Exicure, Inc.

https://www.exicuretx.com

Industry

Biotechnology

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Open

13.30

Mkt cap

32M

Volume

35K

High

13.30

P/E Ratio

-6.14

52-wk high

36.00

Low

12.07

Div yield

N/A

52-wk low

1.44

Exicure, Inc. (NASDAQ:XCUR) shares surged 179.9% in pre-market trading after receiving a Nasdaq listing extension. Other notable pre-market movers include Zeo Energy Corp. (NASDAQ:ZEO) up 288.9%, Telesis Bio, Inc. (NASDAQ:TBIO) up 138.4%, and Venus Concept Inc. (NASDAQ:VERO) up 82.8%.

Portfolio Pulse from Avi Kapoor

September 19, 2024 | 9:26 am

Darden Restaurants, Steelcase, FactSet Research, Exicure, and FedEx are key stocks to watch as they report earnings or receive significant updates. Darden and FactSet are expected to release earnings before the market opens, while FedEx will report after the closing bell. Steelcase reported better-than-expected earnings but missed sales estimates, and Exicure received a Nasdaq extension.

Portfolio Pulse from Avi Kapoor

September 19, 2024 | 6:30 am

Exicure Inc (NASDAQ:XCUR) shares soared in after-hours trading following an announcement of a Nasdaq listing extension. The company must comply with listing criteria by Nov. 14. Exicure recently regained compliance with Nasdaq's minimum bid price and converted $1 million of debt to equity. The stock, a low-float micro-cap, more than doubled, reaching new 52-week highs.

Portfolio Pulse from Adam Eckert

September 18, 2024 | 8:51 pm

Exicure shares rose after the company announced it received an extension from the Nasdaq Hearings Panel, which is likely to provide the company more time to meet listing requirements.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 8:05 pm

Exicure has received an extension from the Nasdaq Hearings Panel, allowing it more time to comply with Nasdaq's listing requirements. This development is crucial for Exicure as it works to maintain its listing status.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 8:02 pm

Insider buying activity has been observed in three penny stocks: Exicure, Amylyx Pharmaceuticals, and Reneo Pharmaceuticals. This insider activity may indicate confidence in the companies' prospects.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 1:01 pm

Exicure, Inc. (NASDAQ:XCUR) shares rose after the company entered into debt-for-equity exchange agreements with DGP and another individual, converting $1 million in debt into equity.

Portfolio Pulse from Dylan Berman

September 16, 2024 | 5:43 pm

Exicure shares rose following the company's announcement of debt-for-equity exchange agreements, which likely improved its financial position.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:55 am

Exicure, Inc. (NASDAQ:XCUR) shares surged over 49% in pre-market trading after the company entered into debt-for-equity exchange agreements and regained Nasdaq compliance. Other notable pre-market movers include NuCana plc (NASDAQ:NCNA) with a 94.4% gain due to positive Phase 2 study data, and Dermata Therapeutics, Inc. (NASDAQ:DRMA) rising 73.4%. On the downside, Rafael Holdings, Inc. (NYSE:RFL) fell 40.1% after previous gains.

Portfolio Pulse from Avi Kapoor

September 16, 2024 | 10:07 am

Coda Octopus, Exicure, RF Industries, AMREP, and Vince Holding are stocks to watch as they report earnings or make significant moves. Coda Octopus and RF Industries are expected to report earnings, while Exicure surged after a debt-for-equity exchange. AMREP reported strong earnings growth, and Vince Holding is expected to post a loss.

Portfolio Pulse from Avi Kapoor

September 16, 2024 | 6:29 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.